CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 551 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence Into Action MOST POPULAR Dad With Cancer Escorts His Autistic Son To School, With The... August 13, 2019 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe September 8, 2024 Making Important Decisions During Cancer: A Survivor’s Story October 26, 2021 Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... January 17, 2023 Load more HOT NEWS Epigenetic Changes Pinpointed as the Cause of Some GISTs Determining Fluid Requirements Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade...
